Pentoxifylline prevents peripheral neurotoxicity induced by paclitaxel chemotherapy in patients with lung cancer
Objective To observe the preventive effect of pentoxifylline on peripheral neurotoxicity in lung cancer patients treated with paclitaxel chemotherapy.Methods A total of 70 patients with lung cancer admitted from June 2021 to June 2022 in our hospital were randomly selected.All patients were treated with paclitaxel combined with immune checkpoint inhibitors.They were randomly divided into two groups:observation group(n=35)and control group(n=35).Patients in the control group were treated with placebo,and those in the observation group were treated with oral pentoxifylline 0.4 g,twice a day to prevent neurotoxicity.The time of symptom onset of peripheral neurotoxicity,performance,the Karnofsky Performance Scale(KPS)score and dosage of paclitaxel used when neurotoxicity occurred were recorded.Peripheral neurotoxicity was evaluated after 2 and 4 cycles of treatment and 6 months after chemotherapy.The time of peripheral neurotoxic symptoms,symptoms,KPS score and the dose of paclitaxel were observed and recorded in detail.Results After 2 and 4 cycles of treatment and 6 months after chemotherapy,the incidence and severity of peripheral neurotoxicity in the observation group were significantly lower than those of the control group(P<0.05).During the treatment,the onset of peripheral neurotoxicity in the observation group was significantly later than that of the control group(P<0.05),and more patients in the observation group were able to use paclitaxel according to the standard dose than those in the control group(P<0.05).After treatment,the KPS score of the observation group was significantly higher than that of the control group(74.23±6.32 points vs 70.56±6.64 points,P<0.05).The treatment cost and average length of stay were significantly lower in the observation group than those of the control group.The efficacy was superior in the observation group than the control group.Conclusion Pentoxifylline prevents paclitaxel-induced neurotoxicity in lung cancer patients to a certain extent.